Skin Lightening and Management of Hyperpigmentation

Skin Lightening & Management of Hyperpigmentation

AK Mohiuddin, Assistant Professor

Department of Pharmacy, World University of Bangladesh 151/8, Green Road, Dhanmondi, Dhaka – 1205, Bangladesh

American Journal of Dermatological Research and Reviews

Skin color, along with hair and eye color, is genetically determined by the amount of melanin found in the top layers of skin. Its varied presence – which accounts for different skin colors – is linked to a population’s historic levels of sun exposure. Skin-lightening is just one of the multiple options for augmenting the skin’s surface appearance, including but not limited to tanning, scarification, makeup, tattooing, face lifts, nose jobs, botox, lip extensions, and piercings. Skin-bleaching practices, such as using skin creams and soaps to achieve a lighter skin tone, are common throughout the world and are triggered by cosmetic reasons that oftentimes have deep historical, economic, sociocultural, and psychosocial roots. The cosmetics industry has traditionally relied on convincing people that they are incomplete without a particular product. Yet, unlike makeup or fake tan, skin-whitening creams base beauty on a racial hierarchy, fueling intolerance and causing serious social harm. Lighter and fairer skin is something that everyone craves for, and celebrities play a massive part in paving the way. Just like ladies, men also aspire to get immaculate, glowing and healthy-looking skin to accentuate their personality and overall looks. It’s for everyone to understand that men really feel shy to discuss the skincare routines as they feel it’s all-girl stuff. But there is no denying that even boys need to uplift and improve their skin texture to feel good. Studies have documented the use of skin fairness products, sometimes referred to as “skin whitening products,” “skin bleaching products,” “depigmenting agents,” in Africa, Europe, North America, and Asia, with prevalence of use ranging from 30 to 80% among various community samples. Skin fairness products include whitening and skin-lightening creams, face washes, deodorants, and lotions. These agents act in different ways to lighten skin, but generally work by suppressing the production of melanin, the pigment which gives human skin its color. While traditionally a female practice, use has become more popular also among men in recent years. These agents selectively target hyperplastic melanocytes and inhibit key regulatory steps in melanin synthesis. Historically marketed to women, companies have recently expanded their offerings to include products designed and marketed specifically for men. Advertisements and packaging overtly claim that products will make consumers’ skin fairer and more even-toned, while product names and the use of well-known models and actors in advertisements imply that they will enhance consumers’ cultural capital via improvements in attractiveness, youthfulness, confidence, and success. The relevance of skin fairness products to public health is highlighted by the scope of the industry, the widespread use of these products, and the potential health risks associated with their use. Skin-whitening cosmetics are a multi-billion-dollar industry pushing the idea that beauty equates with white skin and that lightening dark skin is both achievable and preferable.

Keywords: skin bleaching; whiteners; hyperpigmentation; fairness creams; melasma; tyrosinase inhibitors; dark skin; melanosomes

Free Full-text PDF

How to cite this article:
AK Mohiuddin.Skin Lightening & Management of Hyperpigmentation.American Journal of Dermatological Research and Reviews, 2019, 2:9

1. Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2017 Dec;32(1):403-425. doi: 10.1080/14756366.2016.1256882. Review. PubMed PMID: 28097901; PubMed Central PMCID: PMC6010116.
2. Shroff H, Diedrichs PC, Craddock N. Skin Color, Cultural Capital, and Beauty Products: An Investigation of the Use of Skin Fairness Products in Mumbai, India. Front Public Health. 2018 Jan 23;5:365. doi: 10.3389/fpubh.2017.00365. eCollection 2017. PubMed PMID: 29410952; PubMed Central PMCID: PMC5787082.
3. Jacobs M, Levine S, Abney K, Davids L. Fifty Shades of African Lightness: A Bio-psychosocial Review of the Global Phenomenon of Skin Lightening Practices. J Public Health Afr. 2016 Dec 31;7(2):552. doi: 10.4081/jphia.2016.552. eCollection 2016 Dec 31. Review. PubMed PMID: 28299156; PubMed Central PMCID: PMC5345401.
4. Rusmadi SZ, Syed Ismail SN, Praveena SM. Preliminary study on the skin lightening practice and health symptoms among female students in Malaysia. J Environ Public Health. 2015;2015:591790. doi: 10.1155/2015/591790. Epub 2015 Nov 26. PubMed PMID: 26693230; PubMed Central PMCID: PMC4674599.
5. Darj E, Infanti JJ, Ahlberg BM, Okumu J. “The fairer the better?” Use of potentially toxic skin bleaching products. Afr Health Sci. 2015 Dec;15(4):1074-80. doi: 10.4314/ahs.v15i4.4. PubMed PMID: 26958006; PubMed Central PMCID: PMC4765398.
6. Mohammed T, Mohammed E, Bascombe S. The evaluation of total mercury and arsenic in skin bleaching creams commonly used in Trinidad and Tobago and their potential risk to the people of the Caribbean. J Public Health Res. 2017 Oct 9;6(3):1097. doi: 10.4081/jphr.2017.1097. eCollection 2017 Dec 13. PubMed PMID: 29291194; PubMed Central PMCID: PMC5736993.PubMed Central PMCID: PMC4765398.
7. Tai C and Sukumaran T. Asia is obsessed with skin whitening – but the backlash is beginning. Web InkStone News.
8. Liu M. Skin whiteners are still in demand, despite health concerns. CNN, September 3, 2018.
9. Karmali N. Thailand’s Richest 2018: Skin-Whitening Craze Continues To Surge Across Asia. Forbes, May 2, 2018.
10. Alrayyes SF, Alrayyes SF, Farooq Dar U. Skin-lightening practices behind the veil: An epidemiological study among Saudi women. J Cosmet Dermatol. 2019 May 6. doi: 10.1111/jocd.12972. [Epub ahead of print] PubMed PMID: 31058398.
11. Gruber JV, Holtz R. Examining the impact of skin lighteners in vitro. Oxid Med Cell Longev. 2013;2013:702120. doi: 10.1155/2013/702120. Epub 2013 Apr 28. PubMed PMID: 23738040; PubMed Central PMCID: PMC3655678.
12. de Suisse M. Do you know the difference between Skin Lightening vs. Skin Brightening? Natural Skin Care Blog, October 19, 2017.
13. The 411: Brightening vs. Whitening vs. Lightening. Bolden Blog, USA May 19, 2018.
14. Spradley N. This Is The Real Difference Between Skin Brightening and Skin Lightening. Essence, September 30, 2016.
15. Smit N, Vicanova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci. 2009 Dec 10;10(12):5326-49. doi: 10.3390/ijms10125326. Review. PubMed PMID: 20054473; PubMed Central PMCID: PMC2801997.
16. Malathi M, Thappa DM. Systemic skin whitening/lightening agents: What is the evidence?. Indian J Dermatol Venereol Leprol 2013;79:842-6
17. The Different Meanings Between: Skin Lightening, Brightening, & Whitening.
18. D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling Pathways in Melanogenesis. Int J Mol Sci. 2016 Jul 15;17(7). pii: E1144. doi: 10.3390/ijms17071144. Review. PubMed PMID: 27428965; PubMed Central PMCID: PMC4964517.
19. Yamaguchi Y, Brenner M, Hearing VJ. The regulation of skin pigmentation. J Biol Chem. 2007 Sep 21;282(38):27557-61. Epub 2007 Jul 16. Review. PubMed PMID: 17635904.
20. Bastonini E, Kovacs D, Picardo M. Skin Pigmentation and Pigmentary Disorders: Focus on Epidermal/Dermal Cross-Talk. Ann Dermatol. 2016 Jun;28(3):279-89. doi: 10.5021/ad.2016.28.3.279. Epub 2016 May 25. Review. PubMed PMID: 27274625; PubMed Central PMCID: PMC4884703.
21. Kamakshi R. Fairness via formulations: a review of cosmetic skin-lightening ingredients. J Cosmet Sci. 2012 Jan-Feb;63(1):43-54. Review. PubMed PMID: 22487451.
22. Maranduca MA, Branisteanu D, Serban DN, Branisteanu DC, Stoleriu G, Manolache N, Serban IL. Synthesis and physiological implications of melanic pigments. Oncol Lett. 2019 May;17(5):4183-4187. doi: 10.3892/ol.2019.10071. Epub 2019 Feb 25. Review. PubMed PMID: 30944614; PubMed Central PMCID: PMC6444329.
23. Del Bino S, Duval C, Bernerd F. Clinical and Biological Characterization of Skin Pigmentation Diversity and Its Consequences on UV Impact. Int J Mol Sci. 2018 Sep 8;19(9). pii: E2668. doi: 10.3390/ijms19092668. Review. PubMed PMID: 30205563; PubMed Central PMCID: PMC6163216.
24. Schlessinger DI, Schlessinger J. Biochemistry, Melanin. [Updated 2019 Apr 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from:
25. Sunar, K., Kumar, U., Deshmukh, S., 2016. Recent Applications of Enzymes in Personal Care Products. In: Dhillon, G.Singh, Kaur, S. (Eds.), Agro-Industrial Wastes as Feedstock for Enzyme Production: Apply and Exploit the Emerging and Valuable Use Options of Waste Biomass. Academic Press, 279–298. ISBN: 9780128023921
26. Serre C, Busuttil V, Botto JM. Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. Int J Cosmet Sci. 2018 Aug;40(4):328-347. doi: 10.1111/ics.12466. Epub 2018 Jul 19. Review. PubMed PMID: 29752874.
27. Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013 Jan-Feb;88(1):76-83. Review. PubMed PMID: 23539007; PubMed Central PMCID: PMC3699939.
28. Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med. 2014 May 1;4(5). pii: a017046. doi: 10.1101/cshperspect.a017046. Review. PubMed PMID: 24789876; PubMed Central PMCID: PMC3996377.
29. Yamaguchi Y, Hearing VJ. Physiological factors that regulate skin pigmentation. Biofactors. 2009 Mar-Apr;35(2):193-9. doi: 10.1002/biof.29. Review. PubMed PMID: 19449448; PubMed Central PMCID: PMC2793097.
30. Nguyen NT, Fisher DE. MITF and UV responses in skin: From pigmentation to addiction. Pigment Cell Melanoma Res. 2019 Mar;32(2):224-236. doi: 10.1111/pcmr.12726. Epub 2018 Aug 3. Review. PubMed PMID: 30019545; PubMed Central PMCID: PMC6336527.
31. Tran TT, Schulman J, Fisher DE. UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res. 2008 Oct;21(5):509-16. doi: 10.1111/j.1755-148X.2008.00498.x. Review. PubMed PMID: 18821855; PubMed Central PMCID: PMC2733367.
32. Juhasz MLW, Levin MK. The role of systemic treatments for skin lightening. J Cosmet Dermatol. 2018 Dec;17(6):1144-1157. doi: 10.1111/jocd.12747. Epub 2018 Aug 21. Review. PubMed PMID: 30133125.
33. Zhu-WY, Zhang RZ. Chapter 13. Skin Lightening Agents. In: Zoe Diana Draelos, Lauren A. Thaman. Cosmetic Formulation of Skin Care Products. Published by CRC Press, June 19, 2005. ISBN 9780849339684
34. Sarkar R, Arora P, Garg KV. Cosmeceuticals for Hyperpigmentation: What is Available? J Cutan Aesthet Surg. 2013 Jan;6(1):4-11. doi: 10.4103/0974-2077.110089. PubMed PMID: 23723597; PubMed Central PMCID: PMC3663177.
35. Schwartz C, Jan A. Hydroquinone. [Updated 2019 Mar 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from:
36. Tse TW. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop? J Dermatolog Treat. 2010 Sep;21(5):272-5. doi: 10.3109/09546630903341945. Review. PubMed PMID: 20095963.
37. Godse KV. Triple combination of hydroquinone, tretinoin and mometasone furoate with glycolic acid peels in melasma. Indian J Dermatol. 2009;54(1):92-3. doi: 10.4103/0019-5154.49005. PubMed PMID: 20049286; PubMed Central PMCID: PMC2800888.
38. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology – a potential health risk. J Cosmet Dermatol. 2005 Jun;4(2):55-9. PubMed PMID: 17166200.
39. Byeon SE, Yi YS, Lee J, Yang WS, Kim JH, Kim J, Hong S, Kim JH, Cho JY. Hydroquinone Exhibits In Vitro and In Vivo Anti-Cancer Activity in Cancer Cells and Mice. Int J Mol Sci. 2018 Mar 19;19(3). pii: E903. doi: 10.3390/ijms19030903. PubMed PMID: 29562668; PubMed Central PMCID: PMC5877764.
40. Nofal A, Ibrahim AM, Nofal E, Gamal N, Osman S. Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. J Cosmet Dermatol. 2019 Feb;18(1):263-270. doi: 10.1111/jocd.12769. Epub 2018 Aug 26. PubMed PMID: 30146802.
41. Grimes PE, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018 Nov 20;5(1):30-36. doi: 10.1016/j.ijwd.2018.09.004. eCollection 2019 Feb. PubMed PMID: 30809577; PubMed Central PMCID: PMC6374710.
42. Zhai H, Maibach HI. Skin-Whitening Agents. In: André O. Barel, Marc Paye, Howard I. Maibach. Handbook of Cosmetic Science and Technology, 3rd Edition, published by CRC Press, 2014. ISBN 9781842145647
43. Natural Skin Whitening Ingredients That Work. Available From:
44. Montazeri M, Emami S, Asgarian-Omran H, Azizi S, Sharif M, Sarvi S, Rezaei F, Sadeghi M, Gohardehi S, Daryani A. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis. Exp Parasitol. 2019 May;200:7-12. doi: 10.1016/j.exppara.2019.03.009. Epub 2019 Mar 20. PubMed PMID: 30904693.
45. de Pietro MA. Kojic acid: What you need to know? MedicalNewsToday, 3 October 2017.
46. Saeedi M, Eslamifar M, Khezri K. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019 Feb;110:582-593. doi: 10.1016/j.biopha.2018.12.006. Epub 2018 Dec 8. Review. PubMed PMID: 30537675.
47. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol. 2010 Nov-Dec;29(6 Suppl):244S-73. doi: 10.1177/1091581810385956. Review. PubMed PMID: 21164073.
48. Stirner M. Kojic Acid Side Effects. Available From:
49. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis. 1996 Jan;57(1 Suppl):36-45. Review. PubMed PMID: 8654129.
50. Azelaic Acid Suspension 10% 30ml. Web
51. National Center for Biotechnology Information. PubChem Database. Azelaic acid, CID=2266, (accessed on May 12, 2019)
52. Faghihi G, Taheri A, Shahmoradi Z, Nilforoushzadeh MA. Solution of Azelaic Acid (20%), Resorcinol (10%) and Phytic Acid (6%) Versus Glycolic Acid (50%) Peeling Agent in the Treatment of Female Patients with Facial Melasma. Adv Biomed Res. 2017 Feb 22;6:9. doi: 10.4103/2277-9175.200784. eCollection 2017. PubMed PMID: 28299301; PubMed Central PMCID: PMC5343614.
53. Dayal S, Sahu P, Dua R. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017 Mar;16(1):35-42. doi: 10.1111/jocd.12260. Epub 2016 Aug 8. PubMed PMID: 27500896.
54. Jacobus Berlitz S, De Villa D, Maschmann Inácio LA, Davies S, Zatta KC, Guterres SS, Külkamp-Guerreiro IC. Azelaic acid-loaded nanoemulsion with hyaluronic acid – a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019 Apr;45(4):642-650. doi: 10.1080/03639045.2019.1569032. Epub 2019 Jan 28. PubMed PMID: 30642209.
55. Hollinger JC, Angra K, Halder RM. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018 Feb;11(2):28-37. Epub 2018 Feb 1. Review. PubMed PMID: 29552273; PubMed Central PMCID: PMC5843359.
56. Saade DS, Maymone MBC, Secemsky EA, Kennedy KF, Vashi NA. Patterns of Over-the-counter Lightening Agent Use among Patients with Hyperpigmentation Disorders: A United States-based Cohort Study. J Clin Aesthet Dermatol. 2018 Jul;11(7):26-30. Epub 2018 Jul 1. PubMed PMID: 30057662; PubMed Central PMCID: PMC6057735.
57. Tehranchinia Z, Saghi B, Rahimi H. Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study. Dermatol Res Pract. 2018 Jul 2;2018:8350317. doi: 10.1155/2018/8350317. eCollection 2018. PubMed PMID: 30079087; PubMed Central PMCID: PMC6051262.
58. Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018 Jan 31;8(1):15-21. doi: 10.5826/dpc.0801a04. eCollection 2018 Jan. PubMed PMID: 29445569; PubMed Central PMCID: PMC5808366.
59. Villarama CD, Maibach HI. Glutathione as a depigmenting agent: an overview. Int J Cosmet Sci. 2005 Jun;27(3):147-53. doi: 10.1111/j.1467-2494.2005.00235.x. PubMed PMID: 18492181.
60. Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012 Apr;23(2):97-102. doi: 10.3109/09546631003801619. Epub 2010 Jun 5. PubMed PMID: 20524875.
61. Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017 Apr 27;10:147-153. doi: 10.2147/CCID.S128339. eCollection 2017. PubMed PMID: 28490897; PubMed Central PMCID: PMC5413479.
62. Chung BY, Choi SR, Moon IJ, Park CW, Kim YH, Chang SE. The Glutathione Derivative, GSH Monoethyl Ester, May Effectively Whiten Skin but GSH Does Not. Int J Mol Sci. 2016 Apr 27;17(5). pii: E629. doi: 10.3390/ijms17050629. PubMed PMID: 27128906; PubMed Central PMCID: PMC4881455.
63. Dilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. J Cosmet Dermatol. 2019 Mar 20. doi: 10.1111/jocd.12910. [Epub ahead of print] Review. PubMed PMID: 30895708.
64. Dadzie OE. Unethical skin bleaching with glutathione. BMJ. 2016 Aug 31;354:i4386. doi: 10.1136/bmj.i4386. PubMed PMID: 27581922.
65. Galarpe C. ‘Glutathione injectables not legal’ – FDA. ABS-CBN News, Jun 01 2011.
66. Cosmetic doctors raise concerns over skin bleacher glutathione. COSMEICS BUSINESS (Regulatory), 5-Sep-2016.
67. Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res. 1998 Aug;11(4):206-12. PubMed PMID: 9711535.
68. de Arriba SG, Naser B, Nolte KU. Risk assessment of free hydroquinone derived from Arctostaphylos Uva-ursi folium herbal preparations. Int J Toxicol. 2013 Nov-Dec;32(6):442-53. doi: 10.1177/1091581813507721. Review. PubMed PMID: 24296864.
69. Inoue Y, Hasegawa S, Yamada T, Date Y, Mizutani H, Nakata S, Matsunaga K, Akamatsu H. Analysis of the effects of hydroquinone and arbutin on the differentiation of melanocytes. Biol Pharm Bull. 2013;36(11):1722-30. PubMed PMID: 24189417.
70. Degen, G.H. Opinion of the Scientific Committee on Consumer Safety (SCCS)—Opinion on the safety of the use of α-arbutin in cosmetic products. Regul. Toxicol. Pharmacol. 2016, 74, 75–76.
71. SCCS, Degen GH. Opinion of the Scientific Committee on Consumer Safety (SCCS)–Opinion on the safety of the use of β-arbutin in cosmetic products. Regul Toxicol Pharmacol. 2015 Dec;73(3):866-7. doi: 10.1016/j.yrtph.2015.10.008. Epub 2015 Oct 19. PubMed PMID: 26482403.
72. Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Inhibitory effects of alpha-arbutin on melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model. Biol Pharm Bull. 2004 Apr;27(4):510-4. PubMed PMID: 15056856.
73. Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54(4):303-9. doi: 10.4103/0019-5154.57602. PubMed PMID: 20101327; PubMed Central PMCID: PMC2807702.
74. Miao F, Shi Y, Fan ZF, Jiang S, Xu SZ, Lei TC. Deoxyarbutin Possesses a Potent Skin-Lightening Capacity with No Discernible Cytotoxicity against Melanosomes. PLoS One. 2016 Oct 24;11(10):e0165338. doi: 10.1371/journal.pone.0165338. eCollection 2016. PubMed PMID: 27776184; PubMed Central PMCID: PMC5077105.
75. Hamed SH, Sriwiriyanont P, deLong MA, Visscher MO, Wickett RR, Boissy RE. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. J Cosmet Sci. 2006 Jul-Aug;57(4):291-308. PubMed PMID: 16957809.
76. Chapter 9. Accessory Nutrients and Phytochemicals. In: Michael T. Murray, Joseph Pizzorno. The Encyclopedia of Healing Foods, published by Simon and Schuster, May 11, 2010. ISBN 1439103445, 9781439103449, Page 142
77. Ríos JL, Giner RM, Marín M, Recio MC. A Pharmacological Update of Ellagic Acid. Planta Med. 2018 Oct;84(15):1068-1093. doi: 10.1055/a-0633-9492. Epub 2018 May 30. Review. PubMed PMID: 29847844.
78. Shakeri A, Zirak MR, Sahebkar A. Ellagic Acid: A Logical Lead for Drug Development? Curr Pharm Des. 2018;24(2):106-122. doi: 10.2174/1381612823666171115094557. PubMed PMID: 29141541.
79. Dahl A, Yatskayer M, Raab S, Oresajo C. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. J Drugs Dermatol. 2013 Jan;12(1):52-8. PubMed PMID: 23377328.
80. Ortiz-Ruiz CV, Berna J, Tudela J, Varon R, Garcia-Canovas F. Action of ellagic acid on the melanin biosynthesis pathway. J Dermatol Sci. 2016 May;82(2):115-22. doi: 10.1016/j.jdermsci.2016.02.004. Epub 2016 Feb 12. PubMed PMID: 26899308.
81. Bae JY, Choi JS, Kang SW, Lee YJ, Park J, Kang YH. Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Exp Dermatol. 2010 Aug;19(8):e182-90. doi: 10.1111/j.1600-0625.2009.01044.x. PubMed PMID: 20113347.
82. Baek B, Lee SH, Kim K, Lim HW, Lim CJ. Ellagic acid plays a protective role against UV-B-induced oxidative stress by up-regulating antioxidant components in human dermal fibroblasts. Korean J Physiol Pharmacol. 2016 May;20(3):269-77. doi: 10.4196/kjpp.2016.20.3.269. Epub 2016 Apr 26. PubMed PMID: 27162481; PubMed Central PMCID: PMC4860369.
83. Yagi A, Takeo S. [Anti-inflammatory constituents, aloesin and aloemannan in Aloe species and effects of tanshinon VI in Salvia miltiorrhiza on heart]. Yakugaku Zasshi. 2003 Jul;123(7):517-32. Review. Japanese. PubMed PMID: 12875235.
84. Chang TS. An updated review of tyrosinase inhibitors. Int J Mol Sci. 2009 May 26;10(6):2440-75. doi: 10.3390/ijms10062440. Review. PubMed PMID: 19582213; PubMed Central PMCID: PMC2705500.
85. Jones K, Hughes J, Hong M, Jia Q, Orndorff S. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res. 2002 Oct;15(5):335-40. PubMed PMID: 12213089.
86. Jin YH, Lee SJ, Chung MH, Park JH, Park YI, Cho TH, Lee SK. Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different action mechanism. Arch Pharm Res. 1999 Jun;22(3):232-6. PubMed PMID: 10403123.
87. Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci. 2009 Sep 15;10(9):4066-87. doi: 10.3390/ijms10094066. Review. PubMed PMID: 19865532; PubMed Central PMCID: PMC2769151.
88. Yang ZQ, Wang ZH, Tu JB, Li P, Hu XY. [The effects of aloesin and arbutin on cultured melanocytes in a synergetic method]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2004 Sep;20(5):369-71. Chinese. PubMed PMID: 15623110.
89. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007 Sep-Oct;20(5):308-13. Review. PubMed PMID: 18045355.
90. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006 Dec;19(6):550-71. Review. PubMed PMID: 17083484.
91. Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014 Aug;19(8):753-7. PubMed PMID: 25422661; PubMed Central PMCID: PMC4235096.
92. Cho YH, Park JE, Lim DS, Lee JS. Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells. J Dermatol Sci. 2017 Oct;88(1):96-102. doi: 10.1016/j.jdermsci.2017.05.019. Epub 2017 Jun 7. PubMed PMID: 28669590.
93. Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma. Dermatol Ther (Heidelb). 2017 Sep;7(3):417-424. doi: 10.1007/s13555-017-0195-0. Epub 2017 Jul 26. PubMed PMID: 28748406; PubMed Central PMCID: PMC5574746.
94. Tan AWM, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2017 Aug;58(3):e105-e108. doi: 10.1111/ajd.12474. Epub 2016 May 13. PubMed PMID: 27173008.
95. Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, Venkataramiah LD, Prabhu N. A Randomised, Open-label, Comparative Study of Tranexamic Acid Microinjections and Tranexamic Acid with Microneedling in Patients with Melasma. J Cutan Aesthet Surg. 2013 Jul;6(3):139-43. doi: 10.4103/0974-2077.118403. PubMed PMID: 24163529; PubMed Central PMCID: PMC3800287.
96. Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Derm Venereol. 2017 Jul 6;97(7):776-781. doi: 10.2340/00015555-2668. Review. PubMed PMID: 28374042.
97. Hsieh PW, Chen WY, Aljuffali IA, Chen CC, Fang JY. Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid. Curr Med Chem. 2013;20(32):4080-92. PubMed PMID: 23931279.
98. Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012 Jun;14(3):150-4. doi: 10.3109/14764172.2012.685478. PubMed PMID: 22506692.
99. Lee DH, Oh IY, Koo KT, Suk JM, Jung SW, Park JO, Kim BJ, Choi YM. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Skin Res Technol. 2014 May;20(2):208-12. doi: 10.1111/srt.12107. Epub 2013 Sep 5. PubMed PMID: 24033822.
100. Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016 Jul;41(5):480-5. doi: 10.1111/ced.12835. Epub 2016 May 2. PubMed PMID: 27135282.
101. Sarma N, Chakraborty S, Poojary SA, Rathi S, Kumaran S, Nirmal B, Felicita J, Sarkar R, Jaiswal P, D’Souza P, Donthula N, Sethi S, Ailawadi P, Joseph B. Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma. Indian Dermatol Online J. 2017 Nov-Dec;8(6):406-442. doi: 10.4103/idoj.IDOJ_187_17. PubMed PMID: 29204385; PubMed Central PMCID: PMC5707834.
102. Zhang L, Tan WQ, Fang QQ, Zhao WY, Zhao QM, Gao J, Wang XW. Tranexamic Acid for Adults with Melasma: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018 Nov 6;2018:1683414. doi: 10.1155/2018/1683414. eCollection 2018. PubMed PMID: 30533427; PubMed Central PMCID: PMC6247725.
103. Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N, Torsekar RG, Somani VK, Arora P, Majid I, Ravichandran G, Singh M, Aurangabadkar S, Arsiwala S, Sonthalia S, Salim T, Shah S. Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group. Indian J Dermatol. 2017 Nov-Dec;62(6):558-577. doi: 10.4103/ijd.IJD_489_17. PubMed PMID: 29263529; PubMed Central PMCID: PMC5724303.
104. Taira N, Katsuyama Y, Yoshioka M, Muraoka O, Morikawa T. Structural Requirements of Alkylglyceryl-l-Ascorbic Acid Derivatives for Melanogenesis Inhibitory Activity. Int J Mol Sci. 2018 Apr 10;19(4). pii: E1144. doi: 10.3390/ijms19041144. PubMed PMID: 29642633; PubMed Central PMCID: PMC5979531.
105. Al-Niaimi F, Chiang NYZ. Topical Vitamin C and the Skin: Mechanisms of Action and Clinical Applications. J Clin Aesthet Dermatol. 2017 Jul;10(7):14-17. Epub 2017 Jul 1. Review. PubMed PMID: 29104718; PubMed Central PMCID: PMC5605218.
106. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004 Aug;43(8):604-7. PubMed PMID: 15304189.
107. Hakozaki T, Takiwaki H, Miyamoto K, Sato Y, Arase S. Ultrasound enhanced skin-lightening effect of vitamin C and niacinamide. Skin Res Technol. 2006 May;12(2):105-13. PubMed PMID: 16626384.
108. Tai SS, Lin CG, Wu MH, Chang TS. Evaluation of depigmenting activity by 8-hydroxydaidzein in mouse B16 melanoma cells and human volunteers. Int J Mol Sci. 2009 Nov 20;10(10):4257-66. doi: 10.3390/ijms10104257. PubMed PMID: 20057943; PubMed Central PMCID: PMC2790106.
109. Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC. A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma. Dermatology. 2003;206(4):316-20. PubMed PMID: 12771472.
110. Yi X, Zhao G, Zhang H, Guan D, Meng R, Zhang Y, Yang Q, Jia H, Dou K, Liu C, Que F, Yin JQ. MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther. 2011 Feb;19(2):362-71. doi: 10.1038/mt.2010.263. Epub 2010 Nov 30. PubMed PMID: 21119619; PubMed Central PMCID: PMC3034856.
111. Taira N, Katsuyama Y, Yoshioka M, Okano Y, Masaki H. 3-O-Glyceryl-2-O-hexyl ascorbate suppresses melanogenesis by interfering with intracellular melanosome transport and suppressing tyrosinase protein synthesis. J Cosmet Dermatol. 2018 Dec;17(6):1209-1215. doi: 10.1111/jocd.12451. Epub 2017 Nov 7. PubMed PMID: 29115012.
112. Ando H, Matsui MS, Ichihashi M. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci. 2010 Jun 18;11(6):2566-75. doi: 10.3390/ijms11062566. Review. PubMed PMID: 20640168; PubMed Central PMCID: PMC2904932.
113. Puvabanditsin P, Vongtongsri R. Efficacy of topical vitamin C derivative (VC-PMG) and topical vitamin E in prevention and treatment of UVA suntan skin. J Med Assoc Thai. 2006 Sep;89 Suppl 3:S65-8. PubMed PMID: 17722304.
114. Yang, Z.; Wang, Y.; Wang, Y.; Zhang, Y. Bioassay-guided screening and isolation of
-glucosidase and tyrosinase inhibitors from leaves of Morus alba. Food Chem. 2012, 131, 617–622.
115. Yuan Q, Zhao L. The Mulberry (Morus alba L.) Fruit-A Review of Characteristic Components and Health Benefits. J Agric Food Chem. 2017 Dec 6;65(48):10383-10394. doi: 10.1021/acs.jafc.7b03614. Epub 2017 Nov 20. Review. PubMed PMID: 29129054.
116. Zhang H, Ma ZF, Luo X, Li X. Effects of Mulberry Fruit (Morus alba L.) Consumption on Health Outcomes: A Mini-Review. Antioxidants (Basel). 2018 May 21;7(5). pii: E69. doi: 10.3390/antiox7050069. Review. PubMed PMID: 29883416; PubMed Central PMCID: PMC5981255.
117. Nattapong S, Omboon L. A new source of whitening agent from a Thai Mulberry plant and its betulinic acid quantitation. Nat Prod Res. 2008 Jun 15;22(9):727-34. doi: 10.1080/14786410601130794. PubMed PMID: 18569714.
118. Lim SH, Choi CI. Pharmacological Properties of Morus nigra L. (Black Mulberry) as A Promising Nutraceutical Resource. Nutrients. 2019 Feb 20;11(2). pii: E437. doi: 10.3390/nu11020437. Review. PubMed PMID: 30791521; PubMed Central PMCID: PMC6412198.
119. Zhang X, Hu X, Hou A, Wang H. Inhibitory effect of 2,4,2′,4′-tetrahydroxy-3-(3-methyl-2-butenyl)-chalcone on tyrosinase activity and melanin biosynthesis. Biol Pharm Bull. 2009 Jan;32(1):86-90. PubMed PMID: 19122286.
120. Zheng ZP, Cheng KW, Zhu Q, Wang XC, Lin ZX, Wang M. Tyrosinase inhibitory constituents from the roots of Morus nigra: a structure-activity relationship study. J Agric Food Chem. 2010 May 12;58(9):5368-73. doi: 10.1021/jf1003607. PubMed PMID: 20297841.
121. Koyu H, Kazan A, Demir S, Haznedaroglu MZ, Yesil-Celiktas O. Optimization of microwave assisted extraction of Morus nigra L. fruits maximizing tyrosinase inhibitory activity with isolation of bioactive constituents. Food Chem. 2018 May 15;248:183-191. doi: 10.1016/j.foodchem.2017.12.049. Epub 2017 Dec 14. PubMed PMID: 29329842.
122. Nerya O, Vaya J, Musa R, Izrael S, Ben-Arie R, Tamir S. Glabrene and isoliquiritigenin as tyrosinase inhibitors from licorice roots. J Agric Food Chem. 2003 Feb 26;51(5):1201-7. PubMed PMID: 12590456.
123. Leyden JJ, Shergill B, Micali G, Downie J, Wallo W. Natural options for the management of hyperpigmentation. J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1140-5. doi: 10.1111/j.1468-3083.2011.04130.x. Epub 2011 May 31. Review. PubMed PMID: 21623927.
124. Costa A, Moisés TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol. 2010 Sep-Oct;85(5):613-20. PubMed PMID: 21152784.
125. Sharma K, Joshi N, Goyal C. Critical review of Ayurvedic Varṇya herbs and their tyrosinase inhibition effect. Anc Sci Life. 2015 Jul-Sep;35(1):18-25. doi: 10.4103/0257-7941.165627. Review. PubMed PMID: 26600663; PubMed Central PMCID: PMC4623628.
126. Quay ER, Chang YC, Graber E. Evidence for Anti-Aging South Korean Cosmeceuticals. J Drugs Dermatol. 2017 Apr 1;16(4):358-363. PubMed PMID: 28403270.
127. Binic I, Lazarevic V, Ljubenovic M, Mojsa J, Sokolovic D. Skin ageing: natural weapons and strategies. Evid Based Complement Alternat Med. 2013;2013:827248. doi: 10.1155/2013/827248. Epub 2013 Jan 29. PubMed PMID: 23431351; PubMed Central PMCID: PMC3569896.
128. Thiele JJ, Hsieh SN, Ekanayake-Mudiyanselage S. Vitamin E: critical review of its current use in cosmetic and clinical dermatology. Dermatol Surg. 2005 Jul;31(7 Pt 2):805-13; discussion 813. Review. PubMed PMID: 16029671.
129. Badreshia-Bansal S, Draelos ZD. Insight into skin lightening cosmeceuticals for women of color. J Drugs Dermatol. 2007 Jan;6(1):32-9. Review. PubMed PMID: 17373159.
130. Kamei Y, Otsuka Y, Abe K. Comparison of the inhibitory effects of vitamin E analogues on melanogenesis in mouse B16 melanoma cells. Cytotechnology. 2009 Apr;59(3):183-90. doi: 10.1007/s10616-009-9207-y. Epub 2009 Jul 1. PubMed PMID: 19568943; PubMed Central PMCID: PMC2774566.
131. Kuwabara Y, Watanabe T, Yasuoka S, Fukui K, Takata J, Karube Y, Okamoto Y, Asano S, Katoh E, Tsuzuki T, Kobayashi S. Topical application of gamma-tocopherol derivative prevents UV-induced skin pigmentation. Biol Pharm Bull. 2006 Jun;29(6):1175-9. PubMed PMID: 16755012.
132. Keen MA, Hassan I. Vitamin E in dermatology. Indian Dermatol Online J. 2016 Jul-Aug;7(4):311-5. doi: 10.4103/2229-5178.185494. PubMed PMID: 27559512; PubMed Central PMCID: PMC4976416.
133. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009 Aug;48(8):896-901. doi: 10.1111/j.1365-4632.2009.04130.x. PubMed PMID: 19659873.
134. Jerajani HR, Mizoguchi H, Li J, Whittenbarger DJ, Marmor MJ. The effects of a daily facial lotion containing vitamins B3 and E and provitamin B5 on the facial skin of Indian women: a randomized, double-blind trial. Indian J Dermatol Venereol Leprol. 2010 Jan-Feb;76(1):20-6. doi: 10.4103/0378-6323.58674. PubMed PMID: 20061726.
135. Thiele JJ, Hsieh SN, Ekanayake-Mudiyanselage S. Vitamin E: critical review of its current use in cosmetic and clinical dermatology. Dermatol Surg. 2005 Jul;31(7 Pt 2):805-13; discussion 813. Review. PubMed PMID: 16029671.
136. Burke KE, Clive J, Combs GF Jr, Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. Nutr Cancer. 2000;38(1):87-97. PubMed PMID: 11341050.
137. Burke KE, Clive J, Combs GF Jr, Nakamura RM. Effects of topical L-selenomethionine with topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. J Am Acad Dermatol. 2003 Sep;49(3):458-72. PubMed PMID: 12963910.
138. Lin JY, Selim MA, Shea CR, Grichnik JM, Omar MM, Monteiro-Riviere NA, Pinnell SR. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol. 2003 Jun;48(6):866-74. PubMed PMID: 12789176.
139. Nestor MS, Berman B, Swenson N. Safety and Efficacy of Oral Polypodium leucotomos Extract in Healthy Adult Subjects. J Clin Aesthet Dermatol. 2015 Feb;8(2):19-23. PubMed PMID: 25741399; PubMed Central PMCID: PMC4345929.
140. Winkelmann RR, Del Rosso J, Rigel DS. Polypodium leucotomos extract: a status report on clinical efficacy and safety. J Drugs Dermatol. 2015 Mar;14(3):254-61. Review. PubMed PMID: 25738847.
141. Aguilera P, Carrera C, Puig-Butille JA, Badenas C, Lecha M, González S, Malvehy J, Puig S. Benefits of oral Polypodium Leucotomos extract in MM high-risk patients. J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1095-100. doi: 10.1111/j.1468-3083.2012.04659.x. Epub 2012 Jul 31. PubMed PMID: 22849563; PubMed Central PMCID: PMC4556114.
142. Goh CL, Chuah SY, Tien S, Thng G, Vitale MA, Delgado-Rubin A. Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study. J Clin Aesthet Dermatol. 2018 Mar;11(3):14-19. Epub 2018 Mar 1. PubMed PMID: 29606995; PubMed Central PMCID: PMC5868779.
143. Nestor M, Bucay V, Callender V, Cohen JL, Sadick N, Waldorf H. Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders. J Clin Aesthet Dermatol. 2014 Mar;7(3):13-7. Review. PubMed PMID: 24688621; PubMed Central PMCID: PMC3970827.
144. Ahmed AM, Lopez I, Perese F, Vasquez R, Hynan LS, Chong B, Pandya AG. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol. 2013 Aug;149(8):981-3. doi: 10.1001/jamadermatol.2013.4294. PubMed PMID: 23740292.
145. Berman B, Ellis C, Elmets C. Polypodium Leucotomos–An Overview of Basic Investigative Findings. J Drugs Dermatol. 2016 Feb;15(2):224-8. Review. PubMed PMID: 26885792; PubMed Central PMCID: PMC5189711.
146. Gombau L, García F, Lahoz A, Fabre M, Roda-Navarro P, Majano P, Alonso-Lebrero JL, Pivel JP, Castell JV, Gómez-Lechon MJ, González S. Polypodium leucotomos extract: antioxidant activity and disposition. Toxicol In Vitro. 2006 Jun;20(4):464-71. Epub 2005 Nov 2. PubMed PMID: 16263237.
147. Middelkamp-Hup MA, Pathak MA, Parrado C, Garcia-Caballero T, Rius-Díaz F, Fitzpatrick TB, González S. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol. 2004 Jan;50(1):41-9. PubMed PMID: 14699363.
148. Kohli I, Shafi R, Isedeh P, Griffith JL, Al-Jamal MS, Silpa-Archa N, Jackson B, Athar M, Kollias N, Elmets CA, Lim HW, Hamzavi IH. The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study. J Am Acad Dermatol. 2017 Jul;77(1):33-41.e1. doi: 10.1016/j.jaad.2017.01.044. Epub 2017 Mar 22. PubMed PMID: 28341348; PubMed Central PMCID: PMC5730054.
149. Parrado C, Philips N, Gilaberte Y, Juarranz A, González S. Oral Photoprotection: Effective Agents and Potential Candidates. Front Med (Lausanne). 2018 Jun 26;5:188. doi: 10.3389/fmed.2018.00188. eCollection 2018. Review. PubMed PMID: 29998107; PubMed Central PMCID: PMC6028556.
150. Murbach TS, Glávits R, Hirka G, Endres JR, Clewell AE, Szakonyiné IP. A 28-day oral toxicology study of an aqueous extract of Polypodium leucotomos (Fernblock(®)). Toxicol Rep. 2017 Sep 12;4:494-501. doi: 10.1016/j.toxrep.2017.09.002. eCollection 2017. PubMed PMID: 28959679; PubMed Central PMCID: PMC5615158.
151. Greatens A, Hakozaki T, Koshoffer A, Epstein H, Schwemberger S, Babcock G, Bissett D, Takiwaki H, Arase S, Wickett RR, Boissy RE. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol. 2005 Jul;14(7):498-508. PubMed PMID: 15946237.
152. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. PubMed PMID: 12100180.
153. Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, Oros-Ovalle C, Fuentes-Ahumada C, González FJ, Martínez-Ramírez JD, Moncada B. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatol Res Pract. 2011;2011:379173. doi: 10.1155/2011/379173. Epub 2011 Jul 21. PubMed PMID: 21822427; PubMed Central PMCID: PMC3142702.
154. Hakozaki T, Takiwaki H, Miyamoto K, Sato Y, Arase S. Ultrasound enhanced skin-lightening effect of vitamin C and niacinamide. Skin Res Technol. 2006 May;12(2):105-13. PubMed PMID: 16626384.
155. Wohlrab J, Kreft D. Niacinamide – mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol. 2014;27(6):311-5. doi: 10.1159/000359974. Epub 2014 Jun 27. Review. PubMed PMID: 24993939.
156. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, Li J, Kelm GR. Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide. J Cosmet Dermatol. 2009 Dec;8(4):260-6. doi: 10.1111/j.1473-2165.2009.00470.x. PubMed PMID: 19958429.
157. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, Li J, Kelm GR. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol. 2007 Mar;6(1):20-6. Review. PubMed PMID: 17348991.
158. Kimball AB, Kaczvinsky JR, Li J, Robinson LR, Matts PJ, Berge CA, Miyamoto K, Bissett DL. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol. 2010 Feb 1;162(2):435-41. doi: 10.1111/j.1365-2133.2009.09477.x. Epub 2009 Aug 28. PubMed PMID: 19845667.
159. Bissett DL, Miyamoto K, Sun P, Li J, Berge CA. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004 Oct;26(5):231-8. doi: 10.1111/j.1467-2494.2004.00228.x. PubMed PMID: 18492135.
160. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005 Jul;31(7 Pt 2):860-5; discussion 865. PubMed PMID: 16029679.
161. Chae GY, Ha BJ. The Comparative Evaluation of Fermented and Non-fermented Soybean Extract on Antioxidation and Whitening. Toxicol Res. 2011 Dec;27(4):205-9. doi: 10.5487/TR.2011.27.4.205. PubMed PMID: 24278573; PubMed Central PMCID: PMC3834387.
162. Waqas MK, Akhtar N, Mustafa R, Jamshaid M, Khan HM, Murtaza G. Dermatological and cosmeceutical benefits of Glycine max (soybean) and its active components. Acta Pol Pharm. 2015 Jan-Feb;72(1):3-11. Review. PubMed PMID: 25850195.
163. Lai J, Xin C, Zhao Y, Feng B, He C, Dong Y, Fang Y, Wei S. Study of active ingredients in black soybean sprouts and their safety in cosmetic use. Molecules. 2012 Oct 1;17(10):11669-79. doi: 10.3390/molecules171011669. PubMed PMID: 23027368; PubMed Central PMCID: PMC6268251.
164. Zhao R, Bruning E, Rossetti D, Starcher B, Seiberg M, Iotsova-Stone V. Extracts from Glycine max (soybean) induce elastin synthesis and inhibit elastase activity. Exp Dermatol. 2009 Oct;18(10):883-6. doi: 10.1111/j.1600-0625.2009.00862.x. Epub 2009 Mar 10. PubMed PMID: 19469891.
165. Paine C, Sharlow E, Liebel F, Eisinger M, Shapiro S, Seiberg M. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001 Apr;116(4):587-95. PubMed PMID: 11286627.
166. Lim TG, Kim JE, Lee SY, Park JS, Yeom MH, Chen H, Bode AM, Dong Z, Lee KW. The daidzein metabolite, 6,7,4′-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1. Int J Mol Sci. 2014 Nov 19;15(11):21419-32. doi: 10.3390/ijms151121419. PubMed PMID: 25415304; PubMed Central PMCID: PMC4264233.
167. Liu-Smith F, Meyskens FL. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. Mol Nutr Food Res. 2016 Jun;60(6):1264-74. doi: 10.1002/mnfr.201500822. Epub 2016 Mar 21. Review. PubMed PMID: 26865001; PubMed Central PMCID: PMC4900912.
168. Chang TS. Isolation, bioactivity, and production of ortho-hydroxydaidzein and ortho-hydroxygenistein. Int J Mol Sci. 2014 Apr 3;15(4):5699-716. doi: 10.3390/ijms15045699. Review. PubMed PMID: 24705463; PubMed Central PMCID: PMC4013590.
169. Huang CC, Hsu BY, Wu NL, Tsui WH, Lin TJ, Su CC, Hung CF. Anti-photoaging effects of soy isoflavone extract (aglycone and acetylglucoside form) from soybean cake. Int J Mol Sci. 2010;11(12):4782-95. doi: 10.3390/ijms11124782. Epub 2010 Nov 24. PubMed PMID: 21614173; PubMed Central PMCID: PMC3100816.
170. Riyanto P, Subchan P, Lelyana R. Advantage of soybean isoflavone as antiandrogen on acne vulgaris. Dermatoendocrinol. 2015 Jul 20;7(1):e1063751. doi: 10.1080/19381980.2015.1063751. eCollection 2015 Jan-Dec. PubMed PMID: 26413190; PubMed Central PMCID: PMC4579974.
171. Naturopath. Lectins in Food. Superpharmacy, August 5, 2018.
172. Minwalla L, Zhao Y, Cornelius J, Babcock GF, Wickett RR, Le Poole IC, Boissy RE. Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system. Pigment Cell Res. 2001 Jun;14(3):185-94. PubMed PMID: 11434566.
173. Moghimipour E. Hydroxy Acids, the Most Widely Used Anti-aging Agents. Jundishapur J Nat Pharm Prod. 2012 Winter;7(1):9-10. Epub 2012 Jan 4. PubMed PMID: 24624144; PubMed Central PMCID: PMC3941867.
174. Tang SC, Yang JH. Dual Effects of Alpha-Hydroxy Acids on the Skin. Molecules. 2018 Apr 10;23(4). pii: E863. doi: 10.3390/molecules23040863. Review. PubMed PMID: 29642579; PubMed Central PMCID: PMC6017965.
175. Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what’s new and what isn’t new but still works well. Facial Plast Surg. 2009 Dec;25(5):329-36. doi: 10.1055/s-0029-1243082. Epub 2009 Dec 18. Review. PubMed PMID: 20024875.
176. Sharad J. Glycolic acid peel therapy – a current review. Clin Cosmet Investig Dermatol. 2013 Nov 11;6:281-8. doi: 10.2147/CCID.S34029. Review. PubMed PMID: 24399880; PubMed Central PMCID: PMC3875240.
177. Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997 Mar;23(3):177-9. PubMed PMID: 9145959.
178. Kalla G, Garg A, Kachhawa D. Chemical peeling–glycolic acid versus trichloroacetic acid in melasma. Indian J Dermatol Venereol Leprol. 2001 Mar-Apr;67(2):82-4. PubMed PMID: 17664715.
179. Javaheri SM, Handa S, Kaur I, Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol. 2001 May;40(5):354-7. PubMed PMID: 11555002.
180. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002 Sep;28(9):828-32; discussion 832. PubMed PMID: 12269877.
181. Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002 Dec;138(12):1578-82. PubMed PMID: 12472345.
182. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. Dermatol Surg. 2004 May;30(5):756-60; discussion 760. PubMed PMID: 15099320.
183. Kligman DE. Tretinoin peels versus glycolic acid peels. Dermatol Surg. 2004 Dec;30(12 Pt 2):1609. PubMed PMID: 15606862.
184. Grover C, Reddu BS. The therapeutic value of glycolic acid peels in dermatology. Indian J Dermatol Venereol Leprol. 2003 Mar-Apr;69(2):148-50. PubMed PMID: 17642863.
185. Erbil H, Sezer E, Taştan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007 Jan;34(1):25-30. PubMed PMID: 17204097.
186. Rendon M, Cardona LM, Bussear EW, Benitez AL, Colón LE, Johnson LA. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study. Cutis. 2008 Nov;82(5):372-8. PubMed PMID: 19090343.
187. Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma. Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):447. doi: 10.4103/0378-6323.66602. PubMed PMID: 20657143.
188. Puri N. Comparative study of 15% TCA peel versus 35% glycolic acid peel for the treatment of melasma. Indian Dermatol Online J. 2012 May;3(2):109-13. doi: 10.4103/2229-5178.96702. PubMed PMID: 23130283; PubMed Central PMCID: PMC3481880.
189. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg. 2005 Feb;31(2):149-54; discussion 154. PubMed PMID: 15762205.
190. Soleymani T, Lanoue J, Rahman Z. A Practical Approach to Chemical Peels: A Review of Fundamentals and Step-by-step Algorithmic Protocol for Treatment. J Clin Aesthet Dermatol. 2018 Aug;11(8):21-28. Epub 2018 Aug 1. PubMed PMID: 30214663; PubMed Central PMCID: PMC6122508.
191. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. Dermatol Surg. 2006 Dec;32(12):1429-36. PubMed PMID: 17199649.
192. Puri N. Efficacy of Modified Jessner’s Peel and 20% TCA Versus 20% TCA Peel Alone for the Treatment of Acne Scars. J Cutan Aesthet Surg. 2015 Jan-Mar;8(1):42-5. doi: 10.4103/0974-2077.155082. PubMed PMID: 25949022; PubMed Central PMCID: PMC4411592.
193. Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, Vedamurty M, Kohli M, Sharad J, Kadhe G, Ahirrao P, Narayanan V, Motlekar SA. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014 Dec;4(2):165-86. doi: 10.1007/s13555-014-0064-z. Epub 2014 Oct 1. PubMed PMID: 25269451; PubMed Central PMCID: PMC4257945.
194. Yamamoto Y, Uede K, Yonei N, Kishioka A, Ohtani T, Furukawa F. Effects of alpha-hydroxy acids on the human skin of Japanese subjects: the rationale for chemical peeling. J Dermatol. 2006 Jan;33(1):16-22. PubMed PMID: 16469079.
195. Kornhauser A, Coelho SG, Hearing VJ. Effects of cosmetic formulations containing hydroxyacids on sun-exposed skin: current applications and future developments. Dermatol Res Pract. 2012;2012:710893. doi: 10.1155/2012/710893. Epub 2012 May 20. PubMed PMID: 22675344; PubMed Central PMCID: PMC3362829.
196. Desai SR. Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014 Aug;7(8):13-7. PubMed PMID: 25161755; PubMed Central PMCID: PMC4142815.
197. Arif T. Salicylic acid as a peeling agent: a comprehensive review. Clin Cosmet Investig Dermatol. 2015 Aug 26;8:455-61. doi: 10.2147/CCID.S84765. eCollection 2015. Review. PubMed PMID: 26347269; PubMed Central PMCID: PMC4554394.
198. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999 Jan;25(1):18-22. PubMed PMID: 9935087.
199. Ranjan R, Sarkar R, Garg VK, Gupta T. A Comparative Study of Two Modalities, 4% Hydroquinone Versus 30% Salicylic Acid in Periorbital Hyperpigmentation and Assessment of Quality of Life Before and After Treatment. Indian J Dermatol. 2016 Jul-Aug;61(4):413-7. doi: 10.4103/0019-5154.185707. PubMed PMID: 27512187; PubMed Central PMCID: PMC4966400.
200. Mohamed Ali BM, Gheida SF, El Mahdy NA, Sadek SN. Evaluation of salicylic acid peeling in comparison with topical tretinoin in the treatment of postinflammatory hyperpigmentation. J Cosmet Dermatol. 2017 Mar;16(1):52-60. doi: 10.1111/jocd.12301. Epub 2016 Dec 15. PubMed PMID: 27976510.
201. Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg. 2006 Mar;32(3):372-5; discussion 375. PubMed PMID: 16640681.
202. Fabbrocini G, De Vita V, Marasca C, Palmisano F, Monfrecola G. Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement. Skin Res Technol. 2013 Nov;19(4):466-73. doi: 10.1111/srt.12070. Epub 2013 Mar 25. PubMed PMID: 23527534.
203. Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res. 1998 Jul;290(7):375-81. PubMed PMID: 9749992.
204. Shigeta Y, Imanaka H, Ando H, Ryu A, Oku N, Baba N, Makino T. Skin whitening effect of linoleic acid is enhanced by liposomal formulations. Biol Pharm Bull. 2004 Apr;27(4):591-4. PubMed PMID: 15056874.
205. Ando H, Funasaka Y, Oka M, Ohashi A, Furumura M, Matsunaga J, Matsunaga N, Hearing VJ, Ichihashi M. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J Lipid Res. 1999 Jul;40(7):1312-6. PubMed PMID: 10393216.
206. Ko GA, Kim Cho S. Ethyl linoleate inhibits α-MSH-induced melanogenesis through Akt/GSK3β/β-catenin signal pathway. Korean J Physiol Pharmacol. 2018 Jan;22(1):53-61. doi: 10.4196/kjpp.2018.22.1.53. Epub 2017 Dec 22. PubMed PMID: 29302212; PubMed Central PMCID: PMC5746512.
207. Lee MH, Kim HJ, Ha DJ, Paik JH, Kim HY. Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci. 2002 Aug;17(4):518-23. PubMed PMID: 12172049; PubMed Central PMCID: PMC3054896.
208. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther. 2006 Sep-Oct;19(5):280-8. Review. PubMed PMID: 17014483.
209. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010 Jul;3(7):20-31. PubMed PMID: 20725554; PubMed Central PMCID: PMC2921758.
210. Desmedt B, Van Hoeck E, Rogiers V, Courselle P, De Beer JO, De Paepe K, Deconinck E. Characterization of suspected illegal skin whitening cosmetics. J Pharm Biomed Anal. 2014 Mar;90:85-91. doi: 10.1016/j.jpba.2013.11.024. Epub 2013 Nov 28. PubMed PMID: 24334193.
211. Nahhas AF, Abdel-Malek ZA, Kohli I, Braunberger TL, Lim HW, Hamzavi IH. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light-induced oxidative stress. Photodermatol Photoimmunol Photomed. 2018 Sep 10. doi: 10.1111/phpp.12423. [Epub ahead of print] Review. PubMed PMID: 30198587.
212. Addor FAS. Antioxidants in dermatology. An Bras Dermatol. 2017 May-Jun;92(3):356-362. doi: 10.1590/abd1806-4841.20175697. Review. PubMed PMID: 29186248; PubMed Central PMCID: PMC5514576.
213. Schalka S. New data on hyperpigmentation disorders. J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 5:18-21. doi: 10.1111/jdv.14411. Review. PubMed PMID: 28805937.
214. Pai VV, Shukla P, Kikkeri NN. Antioxidants in dermatology. Indian Dermatol Online J. 2014 Apr;5(2):210-4. doi: 10.4103/2229-5178.131127. PubMed PMID: 24860765; PubMed Central PMCID: PMC4030358.
215. Kim YC, Choi SY, Park EY. Anti-melanogenic effects of black, green, and white tea extracts on immortalized melanocytes. J Vet Sci. 2015;16(2):135-43. Epub 2015 Jan 30. PubMed PMID: 25643794; PubMed Central PMCID: PMC4483495.
216. Mallick S, Singh SK, Sarkar C, Saha B, Bhadra R. Human placental lipid induces melanogenesis by increasing the expression of tyrosinase and its related proteins in vitro. Pigment Cell Res. 2005 Feb;18(1):25-33. PubMed PMID: 15649149.
217. Kim E, Hwang K, Lee J, Han SY, Kim EM, Park J, Cho JY. Skin Protective Effect of Epigallocatechin Gallate. Int J Mol Sci. 2018 Jan 6;19(1). pii: E173. doi: 10.3390/ijms19010173. PubMed PMID: 29316635; PubMed Central PMCID: PMC5796122.
218. Choi SY, Kim YC. Whitening effect of black tea water extract on brown Guinea pig skin. Toxicol Res. 2011 Sep;27(3):153-60. doi: 10.5487/TR.2011.27.3.153. PubMed PMID: 24278566; PubMed Central PMCID: PMC3834380.
219. OyetakinWhite P, Tribout H, Baron E. Protective mechanisms of green tea polyphenols in skin. Oxid Med Cell Longev. 2012;2012:560682. doi: 10.1155/2012/560682. Epub 2012 Jun 26. Review. PubMed PMID: 22792414; PubMed Central PMCID: PMC3390139.
220. Zhang J, Lei Z, Huang Z, Zhang X, Zhou Y, Luo Z, Zeng W, Su J, Peng C, Chen X. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget. 2016 Nov 29;7(48):79557-79571. doi: 10.18632/oncotarget.12836. PubMed PMID: 27791197; PubMed Central PMCID: PMC5346735.
221. An BJ, Kwak JH, Son JH, Park JM, Lee JY, Park TS, Kim SY, Kim YS, Jo C, Byun MW. Physiological activity of irradiated green tea polyphenol on the human skin. Am J Chin Med. 2005;33(4):535-46. PubMed PMID: 16173528.
222. Dumoulin M, Gaudout D, Lemaire B. Clinical effects of an oral supplement rich in antioxidants on skin radiance in women. Clin Cosmet Investig Dermatol. 2016 Oct 18;9:315-324. eCollection 2016. PubMed PMID: 27799805; PubMed Central PMCID: PMC5076548.
223. Ellijimi C, Ben Hammouda M, Othman H, Moslah W, Jebali J, Mabrouk HB, Morjen M, Haoues M, Luis J, Marrakchi N, Essafi-Benkhadir K, Srairi-Abid N. Helix aspersa maxima mucus exhibits antimelanogenic and antitumoral effects against melanoma cells. Biomed Pharmacother. 2018 May;101:871-880. doi: 10.1016/j.biopha.2018.03.020. Epub 2018 Mar 22. PubMed PMID: 29635896.
224. Kim K. Effect of ginseng and ginsenosides on melanogenesis and their mechanism of action. J Ginseng Res. 2015 Jan;39(1):1-6. doi: 10.1016/j.jgr.2014.10.006. Epub 2014 Nov 24. Review. PubMed PMID: 25535470; PubMed Central PMCID: PMC4268563.
225. Lee CS, Nam G, Bae IH, Park J. Whitening efficacy of ginsenoside F1 through inhibition of melanin transfer in cocultured human melanocytes-keratinocytes and three-dimensional human skin equivalent. J Ginseng Res. 2019 Apr;43(2):300-304. doi: 10.1016/j.jgr.2017.12.005. Epub 2018 Jan 31. PubMed PMID: 30962737; PubMed Central PMCID: PMC6437421.
226. Lee Y, Kim KT, Kim SS, Hur J, Ha SK, Cho CW, Choi SY. Inhibitory effects of ginseng seed on melanin biosynthesis. Pharmacogn Mag. 2014 Apr;10(Suppl 2):S272-5. doi: 10.4103/0973-1296.133271. PubMed PMID: 24991102; PubMed Central PMCID: PMC4078335.
227. Jiménez Z, Kim YJ, Mathiyalagan R, Seo KH, Mohanan P, Ahn JC, Kim YJ, Yang DC. Assessment of radical scavenging, whitening and moisture retention activities of Panax ginseng berry mediated gold nanoparticles as safe and efficient novel cosmetic material. Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):333-340. doi: 10.1080/21691401.2017.1307216. Epub 2017 Apr 9. PubMed PMID: 28393568.
228. Lee JO, Kim E, Kim JH, Hong YH, Kim HG, Jeong D, Kim J, Kim SH, Park C, Seo DB, Son YJ, Han SY, Cho JY. Antimelanogenesis and skin-protective activities of Panax ginseng calyx ethanol extract. J Ginseng Res. 2018 Jul;42(3):389-399. doi: 10.1016/j.jgr.2018.02.007. Epub 2018 Feb 21. PubMed PMID: 29983620; PubMed Central PMCID: PMC6026384.
229. Yang Y, Ren C, Zhang Y, Wu X. Ginseng: An Nonnegligible Natural Remedy for Healthy Aging. Aging Dis. 2017 Dec 1;8(6):708-720. doi: 10.14336/AD.2017.0707. eCollection 2017 Dec. Review. PubMed PMID: 29344412; PubMed Central PMCID: PMC5758347.
230. Lee DY, Jeong YT, Jeong SC, Lee MK, Min JW, Lee JW, Kim GS, Lee SE, Ahn YS, Kang HC, Kim JH. Melanin Biosynthesis Inhibition Effects of Ginsenoside Rb2 Isolated from Panax ginseng Berry. J Microbiol Biotechnol. 2015 Dec 28;25(12):2011-5. doi: 10.4014/jmb.1505.05069. PubMed PMID: 26437949.
231. Song M, Mun JH, Ko HC, Kim BS, Kim MB. Korean red ginseng powder in the treatment of melasma: an uncontrolled observational study. J Ginseng Res. 2011 Jun;35(2):170-5. doi: 10.5142/jgr.2011.35.2.170. PubMed PMID: 23717059; PubMed Central PMCID: PMC3659531.
232. Time for a reality check on skin lightening creams. The Conversation, September 11, 2012.
233. Sharma R, Abrol S, Wani M. Misuse of topical corticosteroids on facial skin. A study of 200 patients. J Dermatol Case Rep. 2017 Mar 31;11(1):5-8. doi: 10.3315/jdcr.2017.1240. eCollection 2017 Mar 31. PubMed PMID: 28539982; PubMed Central PMCID: PMC5439689.
234. Pal D, Biswas P, Das S, De A, Sharma N, Ansari A. Topical Steroid Damaged/Dependent Face (TSDF): A Study from a Tertiary Care Hospital in Eastern India. Indian J Dermatol. 2018 Sep-Oct;63(5):375-379. doi: 10.4103/ijd.IJD_218_17. PubMed PMID: 30210157; PubMed Central PMCID: PMC6124224.
235. Ashique KT, Chandrasekhar D. Role of Clinical Pharmacist in Cosmeto-vigilance of Misuse and Abuse of Topical Corticosteroids. Indian J Dermatol. 2017 Mar-Apr;62(2):213. doi: 10.4103/ijd.IJD_686_16. PubMed PMID: 28400646; PubMed Central PMCID: PMC5363150.
236. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014 Oct;5(4):416-25. doi: 10.4103/2229-5178.142483. Review. PubMed PMID: 25396122; PubMed Central PMCID: PMC4228634.
237. Skin-lightening cosmetics: frequent, potentially severe adverse effects. Prescrire Int. 2011 Sep;20(119):209-13, 215. Review. PubMed PMID: 21954516.
238. Lartey M, Krampa FD, Abdul-Rahman M, Quarcoo NL, Yamson P, Hagan PG, Tettey Y, Gyasi R, Adjei AA. Use of skin-lightening products among selected urban communities in Accra, Ghana. Int J Dermatol. 2017 Jan;56(1):32-39. doi: 10.1111/ijd.13449. PubMed PMID: 27943305.
239. Mistry N, Shapero J, Kundu RV, Shapero H. Toxic effects of skin-lightening products in Canadian immigrants. J Cutan Med Surg. 2011 Sep-Oct;15(5):254-8. PubMed PMID: 21962184.
240. Mahé A. The practice of skin-bleaching for a cosmetic purpose in immigrant communities. J Travel Med. 2014 Jul-Aug;21(4):282-7. doi: 10.1111/jtm.12106. Epub 2014 Mar 11. Review. PubMed PMID: 24612323.
241. Benn EK, Alexis A, Mohamed N, Wang YH, Khan IA, Liu B. Skin Bleaching and Dermatologic Health of African and Afro-Caribbean Populations in the US: New Directions for Methodologically Rigorous, Multidisciplinary, and Culturally Sensitive Research. Dermatol Ther (Heidelb). 2016 Dec;6(4):453-459. Epub 2016 Nov 11. PubMed PMID: 27837412; PubMed Central PMCID: PMC5120641.
242. Dlova N, Hamed SH, Tsoka-Gwegweni J, Grobler A, Hift R. Women’s perceptions of the benefits and risks of skin-lightening creams in two South African communities. J Cosmet Dermatol. 2014 Sep;13(3):236-41. doi: 10.1111/jocd.12104. PubMed PMID: 25196692.
243. Jose, A., & Ray, J. G. (2018). Toxic content of certain commercially available fairness creams in Indian market. Cogent Medicine, 5(1), 1433104.
244. Not Just Virat Kohli, Here Are Other Celebs Who Said No To Endorsements On Ethical Grounds. SCOOPWHOOP, Sep 14, 2017.

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).

This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.